25.11.2014 • NewsOricaBlackstoneDede Willams

Orica to Sell Chemicals Business to Blackstone for $652 million

In a deal expected to be finalized early next year. Australian explosives manufacturer Orica has agreed to sell its chemicals business to US private equity investor Blackstone for A$750 million ($653 million).

Orica said in August that it had decided to sell or spin off its chemicals business, realizing a long-held plan to become solely a mining business. Now it says that, compared with a demerger, a sale will likely create more value for shareholders.

The chemicals business sale, which reports said fell short of analyst price estimates of as much as A$1 billion, includes trading businesses in Australia, New Zealand and Latin America and the Australian chloralkali manufacturing business. It also includes food and nutrition supplier Bronson & Jacobs.
Orica also announced plans to cut 500 jobs next year, adding to the 1,300 positions that have been axed over the past two years.

Combined with other cost cutting, the job cuts could result in pretax financial benefits of A$140 million-170 million next year and a further A$60-80 million in 2016, the company said.

"Orica's cost base is being reset and the company better positioned to meet customers' needs in dynamic market conditions," managing director and chief executive Ian Smith remarked.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.